Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Microscopic colitis

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Microscopic colitis itself usually follows a non-emergency course, but profound dehydration, acute kidney injury, severe electrolyte disturbance, fever, peritonism, visible bleeding or haemodynamic compromise is not routine disease. Stabilise such a patient and investigate infection, inflammatory bowel disease, ischaemia or another acute colitis rather than attributing danger signs to a previous microscopic-colitis label.

Synopsis

Recognise microscopic colitis as a treatable cause of chronic watery diarrhoea, obtain diagnostic biopsies despite normal mucosa, exclude important mimics and use budesonide safely.

  • Think of microscopic colitis in persistent watery, usually non-bloody diarrhoea with urgency, nocturnal stools or faecal incontinence, particularly in an older adult.
  • A macroscopically normal colonoscopy does not exclude the diagnosis; histology from appropriately labelled right- and left-colon biopsies is the decisive investigation.
  • Collagenous colitis shows a thickened subepithelial collagen band, while lymphocytic colitis shows increased intraepithelial lymphocytes; clinical management overlaps substantially.
  • Review proton-pump inhibitors, NSAIDs, selective serotonin reuptake inhibitors and other temporally related medicines, but describe associations carefully and do not stop essential treatment without agreement.
  • Exclude infection, coeliac disease and bile acid diarrhoea where the history supports them, because coexistence or a convincing mimic can explain incomplete response.
  • Oral budesonide is first-line induction for active disease; a relevant UK product licence specifies 9 mg each morning, generally for a time-limited course.
  • Relapse after withdrawal is common. Reconfirm the diagnosis and competing causes before a specialist uses the lowest effective maintenance strategy.
  • Microscopic colitis is not managed with the colorectal dysplasia-surveillance programme used for longstanding ulcerative colitis solely because the word colitis appears in its name.

Key red flags

Inflammatory or malignant alternative

Visible bleeding, progressive iron deficiency, marked inflammatory response, abdominal mass or persistent unexplained weight loss is atypical and requires investigation for cancer, conventional IBD, ischaemia or another organic disorder.

Physiological complication

Orthostatic symptoms, oliguria, confusion, tachycardia or muscle weakness suggest volume or electrolyte depletion from high stool output. Assess urgently and correct deficits while determining whether an acute alternative is present.

Investigation priorities

01
Colonoscopy with segmental biopsiesFirst step

Obtain diagnostic tissue and exclude macroscopic colitis, neoplasia or another lower-gastrointestinal cause.

Management branches

DiagnosisConfirm histology before chronic treatment

Watery diarrhoea persists and initial assessment has not shown an obvious infectious or structural cause.

  1. Characterise frequency, nocturnal symptoms, blood, urgency, weight change, exposures, previous surgery and medicines, while checking hydration and warning features.
  2. Send targeted stool and blood tests, including coeliac serology, and arrange lower-GI endoscopy when microscopic colitis remains plausible.
  3. Request multiple right- and left-colon biopsies even if mucosa appears normal, clearly stating the clinical suspicion to endoscopy and pathology teams.
  4. Reconcile histology with symptoms and exclude a stronger alternative before attaching a durable diagnosis or starting recurrent steroid treatment.

Key medicines

Oral budesonideFor active microscopic colitis, use the selected licensed formulation at 9 mg each morning for the SmPC-defined induction course, usually up to eight weeks.Check the formulation, hepatic impairment, infection, diabetes, hypertension, osteoporosis, glaucoma, cataract, psychiatric history and CYP3A interactions. Tapering and maintenance differ by product and specialist plan.
Maintenance budesonideFor frequent relapse after successful induction, a gastroenterologist may use 6 mg each morning or the lowest effective licensed regimen with scheduled reassessment.Do not regard long-term budesonide as risk free. Reassess need by twelve months or sooner under the relevant SmPC, minimise exposure and monitor systemic glucocorticoid complications.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BSG chronic diarrhoea guidelineInvestigation of chronic diarrhoea, including colonic biopsy strategy and alternative causes.
  • Budesonide CR capsules SmPCLicensed induction and maintenance posology plus contraindications, interactions and safety information.
  • Budenofalk capsules SmPCProduct-specific induction, relapse maintenance and scheduled review wording.
  • NICE coeliac disease guidelineCorrect serological testing and confirmation when coeliac disease is a mimic or comorbidity.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom